Skip to content

NASDAQ · large · thesis board

BGNE Beigene

IO / TIGIT and solid tumor portfolio

View race

Thesis

Editorial summary — not a primary filing

Oncology pipeline breadth including IO combinations in lung cancer.

Next gate

2027-01-30EstimatedPh3 readout

Lung IO readout

170 days · Estimated: Estimated window

Survive-to-Event

ok

Cash covers the next gate with ~12 months spare (curated estimate).

Unverified estimate — not from a live SEC parse

Cash runway (~540d)100%
Days to gate (170d)31%
Show math

$3.2B cash ÷ $180M/mo burn ≈ 540 days. Source: curated SEC quarter figures.

Cash $3.2B as of 2026-03-31 (SEC)

Pipeline spine

  1. Preclinical
  2. Ph1
  3. Ph2
  4. Ph3
  5. Filed
  6. Approved

Rivals in this race

Open race →
AZNApprovedokMRKApprovedokSMMTFiledok

Risks

  • Competitive IO landscape
  • Geographic mix
  • Pipeline attrition
  • Pricing

Source trail

  1. SECCash from latest reported quarter (curated)as of 2026-03-31
  2. ClinicalTrials.govNCT04746924as of 2026-07-01
  3. CompanyIR / press disclosuresas of 2026-07-01